Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicholas Mayfield

Ophthalmology Houston, TX Medical Doctor

NPI 1467479089 CMS profile 111412

2727 Gramercy, Suite 200, Houston, TX 77025

Open in the dashboard

General payments

$4,735

226 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Mayfield of Houston, TX is reported in the CMS Open Payments database as having received $4,735 across 226 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,199 47
2024 General $1,032 42
2023 General $653 29
2022 General $590 33
2021 General $473 24
2020 General $237 15
2019 General $551 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Mayfield
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Nicholas Mayfield were reported at $1,199. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Nicholas Mayfield Ophthalmology median Middle half National median
2019 $551 $258 $104–$655 $163
2020 $237 $126 $45–$321 $114
2021 $473 $205 $76–$534 $132
2022 $590 $266 $100–$678 $149
2023 $653 $308 $117–$745 $160
2024 $1,032 $340 $127–$846 $164
2025 $1,199 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $1,330 74 payments
  2. Genentech USA, Inc. $573 31 payments
  3. Alimera Sciences, Inc. $539 25 payments
  4. Apellis Pharmaceuticals, Inc. $398 17 payments
  5. Allergan Inc. $383 26 payments
  6. AbbVie, Inc. $237 12 payments
  7. Astellas Pharma US Inc $224 9 payments
  8. Alcon Vision LLC $190 3 payments
  9. ANI Pharmaceuticals, Inc. $190 8 payments
  10. Tarsus Pharmaceuticals, Inc. $183 3 payments
  11. Other $489 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,735 226 payments
Products named General payments · program years 2019–2025
  1. EYLEA $845 46 payments
  2. EYLEA HD $485 28 payments
  3. OZURDEX $430 29 payments
  4. VABYSMO $421 20 payments
  5. Syfovre $377 16 payments
  6. ILUVIEN treatment of diabetic macular edema in patients who have been previously treated with corticosteroid $336 11 payments
  7. Lucentis $329 19 payments
  8. YUTIQ $289 9 payments
  9. ILUVIEN Ophthalmology $261 16 payments
  10. SUSVIMO $242 13 payments
  11. Other $1,513 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

248

Median for Ophthalmology: 891

Drug cost

$25,594

Median for Ophthalmology: $68,233

Branded share of claims

77.4%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ilevro Nepafenac Brand 30 $13,702
Combigan Brimonidine Tartrate/Timolol Brand 15 $5,375
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 21 $2,999
Prednisolone Acetate Generic 31 $1,556
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 126 $1,526
Brimonidine Tartrate Generic 12 $341
Dorzolamide Hcl Generic 13 $96

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$2,786,409

Of which drugs: $2,429,840

Medicare patients

731

Average age 78

Services billed

44,858

427 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Chronic kidney disease 41%
Diabetes 40%
Ischemic heart disease 34%
Heart failure 23%
Atrial fibrillation 22%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 109 34,140 $925,348
Injection, aflibercept, 1 mg J0178 Office 154 1,224 $789,489
Injection, aflibercept hd, 1 mg J0177 Office 55 1,720 $439,347
Injection, ranibizumab, 0.1 mg J2778 Office 33 562 $69,663
Injection, dexamethasone, intravitreal implant, 0.1 mg J7312 Office 24 336 $52,875
Injection, bevacizumab, 10 mg J9035 Office 160 546 $30,057

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $191
$191 — 1,720
Syfovre
  • Apellis Pharmaceuticals, Inc. $150
$150 — —
ILUVIEN
  • Alimera Sciences, Inc. $130
$130 — —
Izervay
  • Astellas Pharma US Inc $95
$95 — —
EYLEA
  • Regeneron Healthcare Solutions, Inc. $74
$74 — 1,224

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record